PLX — Protalix BioTherapeutics, Inc.

—
NYSE · Health Care · Biotechnology · CIK 1006281 ·
Last close
$2.88
Market Cap
$242.84M
52W High
$3.19
52W Low
$1.65
ADV30
993,518
Next earnings
2026-11-10
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 21,925,000 14,049,000 4,047,000 3,961,000 118,242,000 22,035,000 37,693,000
Jun 2026 19,896,000 12,134,000 4,672,000 3,777,000 110,336,000 27,420,000 38,932,000
Mar 2026 33,750,000 29,623,000 21,146,000 18,317,000 102,336,000 41,001,000 35,107,000
Dec 2025 9,122,000 4,503,000 -4,658,000 -5,504,000 82,346,000 14,680,000 34,116,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$17,559,000
Investing CF
$-14,335,000
Financing CF
$4,879,000
CapEx
$-2,494,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-358,942,000
Inventory
$34,297,000
Receivables
$13,913,000
ST Investments
$26,503,000
EBIT TTM
$26,941,000
Pretax Income TTM
$25,847,000
Interest Exp TTM
$1,094,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$84,693,000
EBITDA
$26,825,000
Free Cash Flow
$11,424,375
Enterprise Value
$217,779,712
Total Cash
$48,538,000
Total Debt
$9,145,000
Shares Out
84,318,923
Trailing EPS
$0.24
Book Value
$0.98
ROE
30.8%
ROA
15.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 52,744,000 -5,500,000 -6,604,000 82,346,000 34,116,000 48,230,000 -11,993,000
Dec 2024 53,399,000 3,917,000 2,932,000 73,417,000 30,206,000 43,211,000 8,674,000
Dec 2023 65,494,000 10,460,000 8,312,000 84,434,000 50,865,000 33,569,000 -1,318,000
Dec 2022 47,638,000 -13,014,000 -14,927,000 55,787,000 66,427,000 -10,640,000 -25,000,000

TTM Snapshot

Revenues TTM
$80,619,000
NetIncome TTM
$18,945,000
OpCashFlow TTM
—
Assets (Latest)
$110,336,000
Forward EPS
$0.62

Max Pain — expiry 2027-02-19

max pain strike: $2.50 · spot: $3.02 · call oi: 4,026 · put oi: 746
Expected Move to 2027-02-19: ±$0.95 (31.46%) — implied range $2.07 – $3.97 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IPSC Century Therapeutics, Inc. $248.79M $1.37 —
LXEO Lexeo Therapeutics, Inc. $234.24M $2.86 —
PROK PROKIDNEY CORP. $229.87M $1.10 —
OCGN Ocugen, Inc. $256.75M $0.76 —
ALLO Allogene Therapeutics, Inc. $257.08M $0.74 —

News headlines (Yahoo Finance, 1h cache)

PLX: Elfabrio Estimates Up, Again
2026-11-11 16:01 · Yahoo
Protalix BioTherapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-11 03:02 · Yahoo
Protalix: Q3 Earnings Snapshot
2026-11-10 11:56 · Yahoo
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
2026-11-10 11:45 · Yahoo
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
2026-11-09 11:45 · Yahoo
Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
2026-11-03 11:50 · Yahoo
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
2026-09-08 10:45 · Yahoo
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
2026-08-12 23:04 · Yahoo
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-12 10:50 · Yahoo
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
2026-08-05 10:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.